Testimonials

USA Europe

Marija Branković MD

Department Head, GI Internal Medicine, Academic Hospital Bezanijska Kosa, Belgrade, Serbia

My team and I evaluated CaroZANG in 20 patients with Crohn’s disease and Ulcerative Colitis. The evaluated patients represent the typical population we see and include both newly diagnosed patients as well as patients with >20 years of medical history. All evaluated patients had signs and symptoms of disease despite being on standard of care therapy . 18/20 of the evaluated patients had increased energy levels and improvement in their symptoms. In several patients we observed reductions in laboratory values of calprotectin and CRP following consumption of CaroZANG. Based on the results observed I recommend my IBD patients to add CaroZANG to their standard therapy.

Srdjan Markovic MD PhD

Department Head, GI Internal Medicine, Academic Hospital Zvezdara, Belgrade, Serbia

I have included 20 of my advanced IBD patients into the CaroZANG evaluation. Most patients had long medical histories of IBD and only about 35% of the evaluated patients had predominant acute inflammatory disease. All evaluated patients were on full standard of care therapy  but still had signs and symptoms of their disease. Following one month of CaroZANG consumption, half of my UC patients had a 50% decrease in the PGA score, as well as reduction in rectal bleeding and stool frequency. 50% of Crohn’s patients had a reduction of the Harvey Bradshaw Index, and 60% had increased energy levels and symptom improvement.

My recommendation is to add CaroZANG to standard of care therapies of IBD patients, including steroids and immunomodulatory biologics drugs.


Zoran Andric MD PhD

Medical Oncology, Academic Hospital Bezanijska Kosa, Belgrade, Serbia

I have evaluated CaroZANG in 10 of my patients with metastatic or terminal cancer receiving treatment with chemotherapy. I observed increased energy levels and functional ability in all 10 patients, as well as faster recovery from chemotherapy side effects relative to previous treatment cycles. Hemoglobin levels consistently increased in patients who had low Hb levels. One patient with CLL who achieved disease control on chemotherapy has remained in remission on CaroZANG. 


My impression is that CaroZANG can be added to standard chemotherapy of cancer patients to improve tolerability.



Clinical evaluation of CaroZANG in 40 IBD patients

Mixed patient population, from newly diagnosed to >30 years of medical history.  All patients were symptomatic at start of evaluation despite being on standard of care therapy. Improvements in patient reported outcomes were observed across the entire population, irrespective of length of medical history or type of standard of care therapy .

Clinical evaluation of CaroZANG in 10 patients with asthma and COPD

All patients were symptomatic at start of evaluation despite being on standard of care therapy. Symptom improvement, improved general condition and reduced use of steroids and bronchodilatators observed after 15 days on CaroZANG .